Irisys was challenged to formulate for oral administration a compound characterized by low solubility in both water and oil, which also degraded rapidly in acid.  As might be expected bioavailability in preliminary trials was poor.  A semi-solid matrix was developed that required heating to liquify for capsule filling. Capsules were enteric coated to protect active ingredient from degradation in acid.  Dog and human studies showed significant improvement in bioavailability.